Design, synthesis and analysis of novel sphingosine kinase-1 inhibitors to improve oral bioavailability
作者:Kendarius J. Butler、Angel A. Castro、Tiffany S. Dwyer、Louise M. Hardwick、Melody C. Iacino、Sara G. Manore、Kevin M. Mays、Caylie A. McGlade、Lisa N. Hair、Erin W. Parker、Mikala R. Smith、Morgan T. Turnow、Matthew R. Wilson、Stephanie R. Woodson、William E. Cotham、Michael D. Walla、Jason C. Hurlbert、T. Christian Grattan
DOI:10.1016/j.bmcl.2021.128329
日期:2021.10
The sphingomyelin pathway is important in cell regulation and determining cellular fate. Inhibition of sphingosine kinase isoform 1 (SK1) within this pathway, leads to a buildup of sphingosine and ceramide, two molecules directly linked to cell apoptosis, while decreasing the intracellular concentration of sphingosine-1-phosphate (S1P), a molecule linked to cellular proliferation. Recently, an inhibitor
鞘磷脂途径在细胞调节和决定细胞命运中很重要。抑制该通路中的鞘氨醇激酶同工型 1 (SK1) 会导致鞘氨醇和神经酰胺的积累,这两种分子与细胞凋亡直接相关,同时降低鞘氨醇-1-磷酸 (S1P) 的细胞内浓度,这是一种与细胞相关的分子增殖。最近,一种能够在体外抑制 SK1 的抑制剂被鉴定出来,但在体内也被证明是无效的。一组化合物,旨在评估用 SK1 对模板抑制剂的羟基萘环区域进行合成修饰的影响,以获得具有更高体内功效的化合物。在这 15 种化合物中,4A 被证明具有 IC50 = 6.55 μM,具有更高的溶解度和体内潜力。